Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 5
2003 5
2004 3
2005 3
2006 3
2007 6
2008 2
2009 2
2010 8
2011 9
2012 9
2013 17
2014 12
2015 14
2016 13
2017 12
2018 14
2019 14
2020 21
2021 21
2022 11
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
irLI or not irLI: That is the question.
Meunier L, De Martin E; REFHEPS group. Meunier L, et al. J Hepatol. 2024 Jan 18:S0168-8278(24)00045-X. doi: 10.1016/j.jhep.2024.01.008. Online ahead of print. J Hepatol. 2024. PMID: 38244847 No abstract available.
Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P, Bourlière M, Di Beo V, Lusivika-Nzinga C, Ramier C, Antwerpes S, Protopopescu C, Lacombe JM, Pol S, Fontaine H, Mourad A, Carrat F, Duracinsky M, Marcellin F; ANRS/AFEF HEPATHER Study Group. Carrieri P, et al. Qual Life Res. 2023 Dec;32(12):3427-3438. doi: 10.1007/s11136-023-03496-w. Epub 2023 Aug 16. Qual Life Res. 2023. PMID: 37587323
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L, Ferreira De Matos C, Lebossé F, Quantin X, Lesage C, Palassin P, Rivet V, Faure S, Pageaux GP, Assenat É, Alric L, Zahhaf A, Larrey D, Witkowski Durand Viel P, Riviere B, Janick S, Dalle S, Maria ATJ, Comont T, Meunier L. Hountondji L, et al. Among authors: larrey d. JHEP Rep. 2023 Mar 7;5(6):100719. doi: 10.1016/j.jhepr.2023.100719. eCollection 2023 Jun. JHEP Rep. 2023. PMID: 37138674 Free PMC article.
Diagnosis and management of hepatic encephalopathy: The French recommendations.
Thabut D, Bouzbib C, Meunier L, Haas M, Weiss N, Louvet A, Imbert-Bismut F, Mochel F, Nadjar Y, Santiago A, Thevenot T, Duhalde V, Oberti F, Francoz C, Coilly A, Hilleret MN, Lebray P, Liou-Schischmanoff A, Barbier L, Duvoux C, Pageaux GP, Bismuth M, Galanaud D, Broucker T, Cadranel JF, Leroy V, Di Martino V, Larrey D, Camus C, Scatton O, De Ledinghen V, Mallat A, Rudler M, Bureau C; Association Française pour l'Etude du Foie (AFEF) group of experts of HE recommendations. Thabut D, et al. Among authors: larrey d. Liver Int. 2023 Apr;43(4):750-762. doi: 10.1111/liv.15510. Epub 2023 Jan 24. Liver Int. 2023. PMID: 36625084 Review.
An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study).
Bronowicki JP, Miailhes P, Hanslik B, Ouzan D, Larrey D, Riachi G, Truchi R, Jouannaud V, Pospait D, Abergel A, Causse X, Perot S, Skrzypski J, De Hautecloque A, Spampinato A, Mariot P, Sogni P; Zephyr Study group. Bronowicki JP, et al. Among authors: larrey d. Health Sci Rep. 2022 Dec 5;6(1):e619. doi: 10.1002/hsr2.619. eCollection 2023 Jan. Health Sci Rep. 2022. PMID: 36479389 Free PMC article.
Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.
Lam L, Fontaine H, Lapidus N, Dorival C, Bellet J, Larrey D, Nahon P, Diallo A, Cagnot C, Lusivika-Nzinga C, Téoulé F, Hejblum G, Bourlière M, Pol S, Carrat F; ANRS/AFEF Hepather study group. Lam L, et al. Among authors: larrey d. Pharmacoepidemiol Drug Saf. 2023 Apr;32(4):486-495. doi: 10.1002/pds.5576. Epub 2022 Dec 5. Pharmacoepidemiol Drug Saf. 2023. PMID: 36444965
171 results